Troglitazone

Caroline Day*, Clifford J. Bailey

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)peer-review

Abstract

Troglitazone was the first thiazolidinedione antihyperglycemic agent to be introduced for the treatment of type 2 diabetes mellitus. It was introduced in 1997, but withdrawn almost immediately (UK) or by 2000 (USA) as evidence emerged of fatal idiosyncratic hepatotoxicity... © 2007

Original languageEnglish
Title of host publicationxPharm
Subtitle of host publicationthe comprehensive pharmacology reference
PublisherElsevier
Number of pages3
ISBN (Print)978-0-08-055232-3
DOIs
Publication statusPublished - Feb 2011

Fingerprint Dive into the research topics of 'Troglitazone'. Together they form a unique fingerprint.

  • Biguanides

    Day, C. & Bailey, C. J., Feb 2011, xPharm: the comprehensive pharmacology reference. Enna, S. J. & Bylund, D. B. (eds.). Elsevier, 3 p.

    Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)peer-review

  • Ciglitazone

    Day, C. & Bailey, C. J., Feb 2011, xPharm: the comprehensive pharmacology reference. Enna, S. J. & Bylund, D. B. (eds.). Elsevier, 2 p.

    Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)peer-review

  • Metformin

    Day, C. & Bailey, C. J., 1 Dec 2011, xPharm: the comprehensive pharmacology reference. Enna, S. J. & Bylund, D. B. (eds.). Elsevier, 4 p.

    Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)peer-review

Cite this